News >

Talazoparib Approaches EU Approval for BRCA-Mutated, HER2-Negative Breast Cancer

OncLive Staff
Published: Monday, Apr 29, 2019

Chris Boshoff, MD, PhD

Chris Boshoff, MD, PhD
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has backed approval of talazoparib (Talzenna) for adult patients with HER2-negative locally advanced or metastatic breast cancer harboring germline BRCA1/2 mutations, according to Pfizer, the manufacturer of the PARP inhibitor.

If approved, the indication would stipulate that eligible patients must have prior treatment with an anthracycline and/or a taxane in the neoadjuvant/adjuvant locally advanced or metastatic setting. Further, eligible patients with HR-positive disease must first have received endocrine-based therapy. The European Commission will now be reviewing the application for a final approval decision.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication
x